Peptide comparisons
45 side-by-side comparisons across the NuVida Vital catalog. Each is built from catalog data — molecular weight, sequence, cost per milligram — plus our published assessment of how strong the underlying literature actually is.
Most-asked comparisons
NAD+ vs 5-Amino-1MQ
Direct NAD+ supply against inhibition of the enzyme that depletes its precursor — two opposite strategies toward the same pool.
AOD-9604 vs Tesamorelin
An hGH fragment selected to exclude growth signaling, against a GHRH analog that deliberately drives the full axis.
GHK-Cu vs BPC-157
Both studied in tissue repair contexts, but one works through matrix remodeling and copper delivery, the other through angiogenic signaling.
BPC-157 vs TB-500
The most frequently co-administered pair in the repair literature, which means they are also the most frequently conflated. They act through entirely different mechanisms.
Cagrilintide vs Semaglutide
Amylin versus incretin signaling — mechanistically independent satiety pathways, which is why they appear together in combination studies.
Ipamorelin vs CJC-1295 (no DAC)
Ghrelin receptor agonism versus GHRH receptor agonism — different receptors, frequently studied together for that reason.
CJC-1295 (no DAC) vs Tesamorelin
Truncated GHRH(1-29) against full-length GHRH(1-44). Sequence length is the whole distinction and it is routinely glossed over.
Epitalon vs Thymosin Alpha-1
Both short peptides with claimed longevity relevance, but with drastically different evidence bases. A useful contrast in how to weigh literature.
NAD+ vs Glutathione
The two dominant redox cofactors in cell biology, routinely confused because both are described as antioxidants — only one of them actually is.
IGF-1 LR3 vs Tesamorelin
Direct IGF-1 receptor agonism versus upstream GHRH stimulation — acting at opposite ends of the same axis.
PT-141 vs Kisspeptin-10
Melanocortin versus kisspeptin signaling. Both act centrally on reproductive pathways through unrelated receptor systems.
MOTS-c vs SS-31
Both target mitochondrial function, but one is a mitochondrially-encoded signaling peptide and the other a cardiolipin-binding structural agent.
Semaglutide vs Retatrutide
The two ends of the incretin design space: a selective GLP-1 analog against a triple agonist.
Tirzepatide vs Retatrutide
Dual versus triple agonism. The question is what glucagon receptor activation adds beyond incretin signaling.
Semax vs Selank
The two best-known Russian neuropeptides, sharing a Pro-Gly-Pro stabilization strategy but derived from different parent molecules.
Semaglutide vs Tirzepatide
Single versus dual incretin receptor engagement — the central comparison in current metabolic pharmacology.